Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Helios
Tokyo, Tokyo-to, Japanhealios.co.jp ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Helios has advanced several iPSC-derived allogeneic cell therapies to clinical trials, including a Phase 2/3 program in ischemic stroke and ongoing development in ARDS and cancer. Recent acquisition of MultiStem assets allows Helios to expand into multipotent adult progenitor cell therapeutics.
- Therapeutic areas
- OncologyOphthalmologyCardiovascularPulmonology
- Modalities
- Cell therapyGene therapyInduced pluripotent stem cell derived therapyAllogeneic cell therapy
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Helios.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helios.